Literature DB >> 9650098

Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis.

A Sedivá1, J Bartůnková, I Kolárová, O Hrusák, V Vávrová, M Macek, C M Lockwood, A C Dunn.   

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) represent a useful diagnostic tool in patients with small vessel vasculitis. Circulating ANCA specific for bactericidal/permeability increasing protein (BPI) have been recently reported in adult patients with cystic fibrosis (CF), an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene with consequent impaired function of a transmembrane chloride channel. To contribute to the better understanding of the significance of ANCA in this disease, we investigated ANCA presence and antigenic specificity in children with CF. Results were correlated with clinical status, immunological data, age and genotype. The indirect immunofluorescence pattern of a total of 71 children with CF indicated that 31 were c-ANCA positive, while seven were p-ANCA positive. In further ELISA studies of ANCA antigenic specificity, 51 out of 66 investigated samples were positive for BPI, and 14 out of 28 were positive for proteinase 3 (PR3). We found an association between levels of antibodies against PR3 with age and Pseudomonas infection. We did not, however, find any correlation between CFTR genotypes, Pseudomonas infection or paediatric parameters and the level of anti-BPI antibodies. High positivity of anti-BPI antibodies were seen even among the youngest CF patients, before the development of clinical signs of CF, indicating that formation of ANCA might be a very early event in the disease. Both anti-BPI and anti-PR3 antibodies may play a significant, although variable role, in the pathogenesis of CF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9650098     DOI: 10.1006/jaut.1997.0186

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

Review 1.  The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.

Authors:  Hendrik Schultz; Jerrold P Weiss
Journal:  Clin Chim Acta       Date:  2007-07-13       Impact factor: 3.786

2.  The role for neutrophil extracellular traps in cystic fibrosis autoimmunity.

Authors:  Sladjana Skopelja; B JoNell Hamilton; Jonathan D Jones; Mei-Ling Yang; Mark Mamula; Alix Ashare; Alex H Gifford; William Fc Rigby
Journal:  JCI Insight       Date:  2016-10-20

3.  Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.

Authors:  R Mahadeva; A C Dunn; R C Westerbeek; L Sharples; D B Whitehouse; N R Carroll; R I Ross-Russell; A K Webb; D Bilton; D A Lomas; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

Review 4.  Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.

Authors:  Adél Molnár; Péter Studinger; Nóra Ledó
Journal:  Front Med (Lausanne)       Date:  2022-06-03

5.  BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients.

Authors:  Ulrika Lindberg; Malin Carlsson; Thomas Hellmark; Mårten Segelmark
Journal:  J Immunol Res       Date:  2015-07-26       Impact factor: 4.818

Review 6.  Vasculitis in Cystic Fibrosis.

Authors:  Francesca Sposito; Paul S McNamara; Christian M Hedrich
Journal:  Front Pediatr       Date:  2020-11-12       Impact factor: 3.418

7.  BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study.

Authors:  Ulrika Lindberg; Malin Carlsson; Claes-Göran Löfdahl; Mårten Segelmark
Journal:  Clin Dev Immunol       Date:  2012-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.